26 completed, 3 recruiting, 3 terminated, 1 active not recruiting. 10 Phase 3, 8 Phase 2, 6 Not applicable, 3 Phase 4, 1 Phase 1.
Follow Epilepsy, Idiopathic Generalized: new trials by email Literature Review of Epilepsy, Idiopathic Generalized trials Research Report on Epilepsy, Idiopathic Generalized
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| High-Intensity Focused Ultrasonic Ablation of the Centromedian Thalamic Nucleus for Treatment of Medically Refractory Generalized Epilepsy in Patients Ages 18 Years to 89 Years Intervention 1, Intervention 2 - Idiopathic Generalized Epilepsy | Not applicable | Not yet recruiting | Oregon Health and Science University | 10 | 2027-02-01 | 2026-09-04 |
| An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures 30mg PRAX-628 - Focal Onset Seizure, Primary Generalized Epilepsy | Phase 2 | Recruiting | Praxis Precision Medicines | 50 | 2025-01-10 | 2025-04-03 |
| Evaluation of Tolerance, Efficacy and Safety of an Hydrolyzed Formula in Infants With IgE/Non-IgE Mediated CMA. Test Formula, Placebo Formula - Cow's Milk Allergy | Not applicable | Active not recruiting | United Pharmaceuticals | 70 | 2024-08-14 | 2025-01-07 |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures BHV-7000, Placebo - Generalized Epilepsy | Phase 2 / Phase 3 | Terminated | Biohaven Therapeutics Ltd. | 27 | 2024-06-20 | 2026-03-24 |
| Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma Allergen-specific immunotherapy(AIT), omalizumab - Allergic Asthma | Unknown | Qianfoshan Hospital | 60 | 2024-06-01 | 2025-01-13 | |
| Repertoire and Properties of Anti-drug Antibodies Involved in Immediate Hypersensitivity in the Operating Room IgG group, IgE group, IgG group + IgE group - Hypersensitivity, Immediate, Peri-operative Injury | Not applicable | Recruiting | Assistance Publique - Hôpitaux de Paris | 40 | 2023-04-12 | 2024-09-19 |
| Idiopathic Generalized Epilepsy Syndromes Epilepsy, Epilepsy, Idiopathic Generalized | Recruiting | Shen Chun-Hong | 200 | 2023-01-01 | 2025-08-27 | |
| Levetiracetam Versus Valproate in Idiopathic Generalized Epilepsy Levetiracetam, Sodium valproate - Treatment of Idiopathic Generalized Epilepsy | Completed | Mazandaran University of Medical Sciences | 169 | 2022-09-03 | 2024-05-02 | |
| RNS System NAUTILUS Study Responsive stimulation, Sham stimulation - Epilepsy, Idiopathic Generalized Epilepsy | Not applicable | Completed | NeuroPace | 100 | 2022-08-09 | 2026-06-08 |
| Study of Attentional Disorders in Patients Suffering From Idiopathic Generalized Epilepsy. Neuropsychological screening and high resolution EEG recording - Idiopathic Generalized Epilepsy | Terminated | University Hospital, Lille | 33 | 2022-04-26 | 2025-05-15 | |
| Exercise for Memory Rehabilitation in Epilepsy Supervised combined endurance and resistance training (CERT), Delayed supervised combined endurance and resistance training (CERT) - Epilepsy, Generalized, Memory Impairment | Not applicable | Completed | University of Alabama at Birmingham | 71 | 2021-07-21 | 2026-03-11 |
| A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy Perampanel - Idiopathic Generalized Epilepsy, Partial Onset Seizures | Completed | Eisai Limited | 191 | 2020-07-20 | 2023-02-09 | |
| Human Epilepsy Project 3 Idiopathic Generalized Epilepsy | Completed | NYU Langone Health | 316 | 2020-03-09 | 2026-06-22 | |
| Cenobamate Open-Label Extension Study for YKP3089C025 Cenobamate - Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy | Phase 3 | Completed | SK Life Science, Inc. | 147 | 2019-08-13 | 2026-06-26 |
| Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures Cenobamate, Placebo - Primary Generalized Epilepsy | Phase 3 | Completed | SK Life Science, Inc. | 169 | 2018-10-03 | 2026-07-02 |
| Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures Levetiracetam, Valproate - Epilepsy, Idiopathic Generalized | Phase 4 | Completed | Mazandaran University of Medical Sciences | 103 | 2018-04-01 | 2022-02-17 |
| CX-8998 for Absence Seizures CX-8998 - Epilepsy | Phase 2 | Completed | Jazz Pharmaceuticals | 7 | 2018-02-25 | 2022-09-08 |
| A Study of Fycompa (Perampanel) in Korean Participants Epilepsy | Completed | Eisai Korea Inc. | 3692 | 2016-07-01 | 2021-08-09 | |
| Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures Lacosamide Tablet, Lacosamide Oral Solution - Epilepsy | Phase 3 | Completed | UCB BIOSCIENCES, Inc. | 239 | 2015-08-03 | 2023-12-14 |
| A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications Lacosamide Tablet, Lasosamide Oral Solution, Placebo Tablet - Epilepsy | Phase 3 | Completed | UCB BIOSCIENCES, Inc. | 242 | 2015-04-01 | 2020-12-17 |
Showing 20 of 35. Sign in to see all of them.
Epilepsy (16) · Seizures (11) · Epilepsy, Generalized (6) · Asthma (4) · Hypersensitivity (3) · Epilepsies, Partial (2) · Epilepsy, Tonic-Clonic (2) · Airway Remodeling (1) · Anaphylaxis (1) · Chronic Urticaria (1) · Dementia (1) · Drug Resistant Epilepsy (1) · Epilepsy, Absence (1) · Familial encephalopathy with neuroserpin inclusion bodies (1)
Nervous System Diseases (21) · Brain Diseases (19) · Central Nervous System Diseases (19) · Pathological Conditions, Signs and Symptoms (15) · Neurologic Manifestations (13) · Signs and Symptoms (13) · Immune System Diseases (7) · Hypersensitivity, Immediate (6) · Bronchial Diseases (4) · Hypersensitivity (4) · Lung Diseases (4) · Lung Diseases, Obstructive (4) · Respiratory Hypersensitivity (4) · Respiratory Tract Diseases (4) · Epilepsy (3)
Omalizumab (6) · Lacosamide (4) · Levetiracetam (4) · Cenobamate (2) · Valproic Acid (2) · Apomorphine (1) · Clemastine (1) · Immunotherapy (1) · Loratadine (1) · Resistance Training (1) · Topiramate (1) · ligelizumab (1) · perampanel (1)
Novartis (4) · UCB BIOSCIENCES, Inc. (4) · Mazandaran University of Medical Sciences (2) · Novartis Pharmaceuticals (2) · SK Life Science, Inc. (2) · UCB Pharma (2) · Assistance Publique - Hôpitaux de Paris (1) · Biohaven Therapeutics Ltd. (1) · Eisai Korea Inc. (1) · Eisai Limited (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Jazz Pharmaceuticals (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · NYU Langone Health (1) · NeuroPace (1)
United States (17) · France (8) · Australia (7) · Germany (7) · Spain (6) · Italy (5) · Poland (5) · South Korea (5) · Bulgaria (4) · China (4) · Czechia (4) · Hungary (4) · Portugal (4) · Slovakia (4) · Belgium (3)
Sunita Misra, MD (2) · Ahmed Raslan, MD (1) · Antony E Shrimpton, PhD (1) · Aurelie Gouel, MD, PhD (1) · Chunhong Shen (1) · Daniel Lowenstein, MD (1) · Jane B. Allendorfer, Ph.D. (1) · Kyung-Up Min, M.D., Ph.D. (1) · Martha Morrell, MD (1)
PMID 19327967, PMID 28086164, PMID 10331611, PMID 10517635, PMID 10595921, PMID 10797443, PMID 11241498, PMID 12103288, PMID 12690085, PMID 15368082, PMID 15521982, PMID 15551335, PMID 16411192, PMID 17625106, PMID 18203205, PMID 18285535, PMID 32917807, PMID 35605481, PMID 39087564, PMID 39460685
2014 (2), 2023 (1), R01HD102723 (1)